Southwest oncology group phase II trial of concurrent carboplatin, etoposide, and radiation for poor-risk stage III non-small-cell lung cancer

Derick H. Lau, John J. Crowley, David R. Gandara, Mark B. Hazuka, Kathy S. Albain, Bryan Leigh, William S. Fletcher, Keith S. Lanier, Wayne L. Keiser, Robert B Livingston

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Purpose: A phase II study was conducted by the Southwest Oncology Group (SWOG) to assess the efficacy and toxicity of concurrent carboplatin, etoposide, and thoracic radiation (XRT) in a defined population of poor-risk patients with stage III non-small-cell lung cancer (NSCLC). Patients and Methods: Patients with stage III NSCLC were eligible if they were excluded from cisplatin-based protocols because of poor pulmonary or renal function, history of congestive heart failure, hearing loss, peripheral neuropathy, or weight loss. Carboplatin 200 mg/m2 daily intravenously days 1, 3, 29, and 31 and etoposide 50 mg/m2 daily intravenously days 1 through 4 and 29 through 32 were administered. Beginning day 1, XRT was delivered at 1.8 to 2.0 Gy daily to a total dose of 61 Gy. Results: Within a period of 1 year, 63 patients were registered and 60 were eligible. Patient characteristics were age 47 to 79 years, performance status 0 to 1 (82%) and 2 (18%), and stages IIIA (60%) and IIIB (40%) NSCLC. The most common grades 3 and 4 toxicities included leukopenia (50%), thrombocytopenia (23%), and esophagitis (15%). There were no treatment-related deaths. The overall confirmed response rate was 29%, and median overall survival was 13 months (95% confidence interval, 11 to 14 months). The 2-year survival rate was 21%. Conclusion: This chemoradiotherapy regimen is well tolerated in poor-risk patients and yields a median survival similar to that of good-risk patients who received cisplatin-based chemoradiotherapy. This chemoradiotherapy regimen will be compared with XRT alone in poor-risk patients with stage III NSCLC in a randomized phase III trial.

Original languageEnglish (US)
Pages (from-to)3078-3081
Number of pages4
JournalJournal of Clinical Oncology
Volume16
Issue number9
StatePublished - Sep 1998
Externally publishedYes

Fingerprint

Carboplatin
Etoposide
Non-Small Cell Lung Carcinoma
Radiation
Chemoradiotherapy
Cisplatin
Survival
Esophagitis
Leukopenia
Peripheral Nervous System Diseases
Hearing Loss
Thrombocytopenia
Weight Loss
Thorax
Survival Rate
Heart Failure
Confidence Intervals
Kidney
Lung
Population

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Southwest oncology group phase II trial of concurrent carboplatin, etoposide, and radiation for poor-risk stage III non-small-cell lung cancer. / Lau, Derick H.; Crowley, John J.; Gandara, David R.; Hazuka, Mark B.; Albain, Kathy S.; Leigh, Bryan; Fletcher, William S.; Lanier, Keith S.; Keiser, Wayne L.; Livingston, Robert B.

In: Journal of Clinical Oncology, Vol. 16, No. 9, 09.1998, p. 3078-3081.

Research output: Contribution to journalArticle

Lau, DH, Crowley, JJ, Gandara, DR, Hazuka, MB, Albain, KS, Leigh, B, Fletcher, WS, Lanier, KS, Keiser, WL & Livingston, RB 1998, 'Southwest oncology group phase II trial of concurrent carboplatin, etoposide, and radiation for poor-risk stage III non-small-cell lung cancer', Journal of Clinical Oncology, vol. 16, no. 9, pp. 3078-3081.
Lau, Derick H. ; Crowley, John J. ; Gandara, David R. ; Hazuka, Mark B. ; Albain, Kathy S. ; Leigh, Bryan ; Fletcher, William S. ; Lanier, Keith S. ; Keiser, Wayne L. ; Livingston, Robert B. / Southwest oncology group phase II trial of concurrent carboplatin, etoposide, and radiation for poor-risk stage III non-small-cell lung cancer. In: Journal of Clinical Oncology. 1998 ; Vol. 16, No. 9. pp. 3078-3081.
@article{e54e982242f549f6b483c8e0964f5ed8,
title = "Southwest oncology group phase II trial of concurrent carboplatin, etoposide, and radiation for poor-risk stage III non-small-cell lung cancer",
abstract = "Purpose: A phase II study was conducted by the Southwest Oncology Group (SWOG) to assess the efficacy and toxicity of concurrent carboplatin, etoposide, and thoracic radiation (XRT) in a defined population of poor-risk patients with stage III non-small-cell lung cancer (NSCLC). Patients and Methods: Patients with stage III NSCLC were eligible if they were excluded from cisplatin-based protocols because of poor pulmonary or renal function, history of congestive heart failure, hearing loss, peripheral neuropathy, or weight loss. Carboplatin 200 mg/m2 daily intravenously days 1, 3, 29, and 31 and etoposide 50 mg/m2 daily intravenously days 1 through 4 and 29 through 32 were administered. Beginning day 1, XRT was delivered at 1.8 to 2.0 Gy daily to a total dose of 61 Gy. Results: Within a period of 1 year, 63 patients were registered and 60 were eligible. Patient characteristics were age 47 to 79 years, performance status 0 to 1 (82{\%}) and 2 (18{\%}), and stages IIIA (60{\%}) and IIIB (40{\%}) NSCLC. The most common grades 3 and 4 toxicities included leukopenia (50{\%}), thrombocytopenia (23{\%}), and esophagitis (15{\%}). There were no treatment-related deaths. The overall confirmed response rate was 29{\%}, and median overall survival was 13 months (95{\%} confidence interval, 11 to 14 months). The 2-year survival rate was 21{\%}. Conclusion: This chemoradiotherapy regimen is well tolerated in poor-risk patients and yields a median survival similar to that of good-risk patients who received cisplatin-based chemoradiotherapy. This chemoradiotherapy regimen will be compared with XRT alone in poor-risk patients with stage III NSCLC in a randomized phase III trial.",
author = "Lau, {Derick H.} and Crowley, {John J.} and Gandara, {David R.} and Hazuka, {Mark B.} and Albain, {Kathy S.} and Bryan Leigh and Fletcher, {William S.} and Lanier, {Keith S.} and Keiser, {Wayne L.} and Livingston, {Robert B}",
year = "1998",
month = "9",
language = "English (US)",
volume = "16",
pages = "3078--3081",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "9",

}

TY - JOUR

T1 - Southwest oncology group phase II trial of concurrent carboplatin, etoposide, and radiation for poor-risk stage III non-small-cell lung cancer

AU - Lau, Derick H.

AU - Crowley, John J.

AU - Gandara, David R.

AU - Hazuka, Mark B.

AU - Albain, Kathy S.

AU - Leigh, Bryan

AU - Fletcher, William S.

AU - Lanier, Keith S.

AU - Keiser, Wayne L.

AU - Livingston, Robert B

PY - 1998/9

Y1 - 1998/9

N2 - Purpose: A phase II study was conducted by the Southwest Oncology Group (SWOG) to assess the efficacy and toxicity of concurrent carboplatin, etoposide, and thoracic radiation (XRT) in a defined population of poor-risk patients with stage III non-small-cell lung cancer (NSCLC). Patients and Methods: Patients with stage III NSCLC were eligible if they were excluded from cisplatin-based protocols because of poor pulmonary or renal function, history of congestive heart failure, hearing loss, peripheral neuropathy, or weight loss. Carboplatin 200 mg/m2 daily intravenously days 1, 3, 29, and 31 and etoposide 50 mg/m2 daily intravenously days 1 through 4 and 29 through 32 were administered. Beginning day 1, XRT was delivered at 1.8 to 2.0 Gy daily to a total dose of 61 Gy. Results: Within a period of 1 year, 63 patients were registered and 60 were eligible. Patient characteristics were age 47 to 79 years, performance status 0 to 1 (82%) and 2 (18%), and stages IIIA (60%) and IIIB (40%) NSCLC. The most common grades 3 and 4 toxicities included leukopenia (50%), thrombocytopenia (23%), and esophagitis (15%). There were no treatment-related deaths. The overall confirmed response rate was 29%, and median overall survival was 13 months (95% confidence interval, 11 to 14 months). The 2-year survival rate was 21%. Conclusion: This chemoradiotherapy regimen is well tolerated in poor-risk patients and yields a median survival similar to that of good-risk patients who received cisplatin-based chemoradiotherapy. This chemoradiotherapy regimen will be compared with XRT alone in poor-risk patients with stage III NSCLC in a randomized phase III trial.

AB - Purpose: A phase II study was conducted by the Southwest Oncology Group (SWOG) to assess the efficacy and toxicity of concurrent carboplatin, etoposide, and thoracic radiation (XRT) in a defined population of poor-risk patients with stage III non-small-cell lung cancer (NSCLC). Patients and Methods: Patients with stage III NSCLC were eligible if they were excluded from cisplatin-based protocols because of poor pulmonary or renal function, history of congestive heart failure, hearing loss, peripheral neuropathy, or weight loss. Carboplatin 200 mg/m2 daily intravenously days 1, 3, 29, and 31 and etoposide 50 mg/m2 daily intravenously days 1 through 4 and 29 through 32 were administered. Beginning day 1, XRT was delivered at 1.8 to 2.0 Gy daily to a total dose of 61 Gy. Results: Within a period of 1 year, 63 patients were registered and 60 were eligible. Patient characteristics were age 47 to 79 years, performance status 0 to 1 (82%) and 2 (18%), and stages IIIA (60%) and IIIB (40%) NSCLC. The most common grades 3 and 4 toxicities included leukopenia (50%), thrombocytopenia (23%), and esophagitis (15%). There were no treatment-related deaths. The overall confirmed response rate was 29%, and median overall survival was 13 months (95% confidence interval, 11 to 14 months). The 2-year survival rate was 21%. Conclusion: This chemoradiotherapy regimen is well tolerated in poor-risk patients and yields a median survival similar to that of good-risk patients who received cisplatin-based chemoradiotherapy. This chemoradiotherapy regimen will be compared with XRT alone in poor-risk patients with stage III NSCLC in a randomized phase III trial.

UR - http://www.scopus.com/inward/record.url?scp=0031720390&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031720390&partnerID=8YFLogxK

M3 - Article

C2 - 9738578

AN - SCOPUS:0031720390

VL - 16

SP - 3078

EP - 3081

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 9

ER -